

## PRESS RELEASE

---

# Camurus to present at SEB Biotech Seminar in Stockholm

**Lund, Sweden — 18 January 2019** — Camurus (NASDAQ STO: CAMX) today announced that that the Company will present at the SEB Biotech Seminar in Stockholm 24 January at 8:30 am. Fredrik Tiberg, President and CEO, will give an update on the company's activities, including the ongoing launch of Buvidal® weekly and monthly depots for the treatment of opioid dependence.

### **About Camurus**

*Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company's proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus' clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit [www.camurus.com](http://www.camurus.com).*

### **For more information**

Fredrik Tiberg, President & CEO

Tel. +46 (0)46 286 46 92

[fredrik.tiberg@camurus.com](mailto:fredrik.tiberg@camurus.com)

Fredrik Joabsson, VP Business Development

Tel. +46 (0)70 776 17 37

[ir@camurus.com](mailto:ir@camurus.com)

This information was submitted for publication at 10.00 am CET on 18 January 2019.